809P Safety profile associated with first-line (1L) encorafenib plus cetuximab (EC) ± mFOLFOX6 and chemotherapy (chemo) ± bevacizumab (bev) in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) (BREAKWATER) | Publicación